252 related articles for article (PubMed ID: 35660765)
1. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
3. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
[TBL] [Abstract][Full Text] [Related]
4. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract][Full Text] [Related]
6. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
[TBL] [Abstract][Full Text] [Related]
8. A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry.
Knudsen BS; Jadhav A; Perry LJ; Thagaard J; Deftereos G; Ying J; Brintz BJ; Zhang W
Lab Invest; 2024 Jun; 104(6):102070. PubMed ID: 38677590
[TBL] [Abstract][Full Text] [Related]
9. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
12. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
13. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
14. Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
Liu J; Zheng Q; Mu X; Zuo Y; Xu B; Jin Y; Wang Y; Tian H; Yang Y; Xue Q; Huang Z; Chen L; Gu B; Hou X; Shen L; Guo Y; Li Y
Sci Rep; 2021 Aug; 11(1):15907. PubMed ID: 34354151
[TBL] [Abstract][Full Text] [Related]
15. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
18. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
[TBL] [Abstract][Full Text] [Related]
19. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
20. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]